Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Taranabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taranabant SCHEMBL13253304 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL501972 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL4024243 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL29434856 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL304925 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253294 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474367 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474366 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3475455 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL16357820 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | disclosed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | CNR1, CNR2, DBN1 | CNR1 1/4885CNR2 2/4885CYP2D6 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.